Examples of using Monotherapy or in combination in English and their translations into Croatian
{-}
-
Colloquial
-
Ecclesiastic
-
Computer
Ilaris can be given as monotherapy or in combination with methotrexate.
Pulmonary embolism or deep vein thrombosis can occur when trametinib is used as monotherapy or in combination with dabrafenib.
The drug used as monotherapy or in combination with other similar drugs in hypertension.
There are no data in humans for dabrafenib as monotherapy or in combination with trametinib.
Mekinist as monotherapy or in combination with dabrafenib can cause rashor acne-like rash.
IntronA was administered at a dose of 3 MIU 3 times a week as monotherapy or in combination with ribavirin.
Male patients taking dabrafenib as monotherapy or in combination with trametinib should be informed of the potential risk for impaired spermatogenesis, which may be irreversible.
Overall, sitagliptin improved glycaemic control when used as monotherapy or in combination treatment see Table 2.
Patients should take dabrafenib as monotherapy or in combination with trametinib at least one hour prior toor two hours after a meal due to the effect of food on dabrafenib absorption see section 5.2.
Trametinib has been reported to decrease LVEF,when used as monotherapy or in combination with dabrafenib see section 4.8.
Dabrafenib as monotherapy or in combination with trametinib is indicated for the treatment of adult patients with unresectableor metastatic melanoma with a BRAF V600 mutation see sections 4.4 and 5.1.
Hypoglycaemia when Eperzan is used as monotherapy or in combination with metformin or pioglitazone.
Table 2: Summary of ADRs occurring in patients with sJIA or pJIA receiving tocilizumab as monotherapy or in combination with MTX.
Dabrafenib dose Used as monotherapy or in combination with trametinib.
Dose adjustment for dabrafenib below 50 mg twice daily is not recommended,whether used as monotherapy or in combination with trametinib.
The recommended dose of dabrafenib,either used as monotherapy or in combination with trametinib, is 150 mg(two 75 mg capsules) twice daily corresponding to a total daily dose of 300 mg.
Trametinib should be used with caution in patients with severe renal impairment when administered as monotherapy or in combination with dabrafenib.
Trametinib as monotherapy or in combination with dabrafenib is indicated for the treatment of adult patients with unresectableor metastatic melanoma with a BRAF V600 mutation see sections 4.4 and 5.1.
The recommended dose of trametinib,either used as monotherapy or in combination with dabrafenib, is 2 mg once daily.
IntronA is administered subcutaneously at a dose of 3 million IU three times a week(every other day) to adult patients,whether administered as monotherapy or in combination with ribavirin.
Cetuximab pharmacokinetics were studied when cetuximab was administered as monotherapy or in combination with concomitant chemotherapyor radiation therapy in clinical studies.
Data are derived from historical experience andclinical studies in multiple myeloma patients in which dexamethasone was used as monotherapy or in combination with placebo.
Opsumit, as monotherapy or in combination, is indicated for the long-term treatment of pulmonary arterial hypertension(PAH)in adult patients of WHO Functional Class(FC) II to III.
Rhabdomyolysis has been reported in patients taking trametinib as monotherapy or in combination with dabrafenib see section 4.8.
Patients should take trametinib as monotherapy or in combination with dabrafenib at least one hour prior toor two hours after a meal due to the effect of food on trametinib absorption see section 4.2 and 5.2.
Dabrafenib should be used with caution in patients with moderate or severe hepatic impairment when administered as monotherapy or in combination with trametinib.
Adempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension(PAH) with WHO Functional Class(FC) II to III to improve exercise capacity.
Trametinib should be used with caution in patients with moderate or severe hepatic impairment when administered as monotherapy or in combination with dabrafenib.
Bortezomib Accord as monotherapy or in combination with pegylated liposomal doxorubicin or dexamethasone is indicated for the treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for haematopoietic stem cell transplantation.
BRIGHTER was a 3-arm randomised active-controlled study that compared 0.5 mg ranibizumab given as monotherapy or in combination with adjunctive laser photocoagulation to laser photocoagulation alone.